Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly, Novo Nordisk Under Government Investigation For Promotion Of Their Diabetes Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

The Attorney General of Texas is looking into Lilly's marketing of Actos while the Massachusetts U.S. Attorney's Office is investigating Novo's promotion of NovoLog, Levemir and Victoza.

You may also be interested in...



Novo Probe By U.S. Expands To Insulin Manufacturing

Massachusetts U.S. Attorney’s office, which is also investigating firm’s marketing, now subpoenas Novo Nordisk for documents relating to potential issues at its plant in Kalundborg, Denmark.

No End In Sight: Pharma Companies Continue To Face Government Probes

No End In Sight: Pharma Companies Continue To Face Government Probes

Related Content

Topics

UsernamePublicRestriction

Register

PS071865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel